Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.
作者信息
Franssen Laurens E, Nijhof Inger S, Couto Suzana, Levin Mark-David, Bos Gerard M J, Broijl Annemiek, Klein Saskia K, Ren Yan, Wang Maria, Koene Harry R, Bloem Andries C, Beeker Aart, Faber Laura M, van der Spek Ellen, Raymakers Reinier, Leguit Roos J, Sonneveld Pieter, Zweegman Sonja, Lokhorst Henk, Mutis Tuna, Thakurta Anjan, Qian Xiaozhong, van de Donk Niels W C J
机构信息
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Department of Exploratory Toxicology, Celgene, San Diego, CA, USA.
出版信息
Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15.
Abstract
摘要
相似文献
1
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.大脑神经酰胺蛋白（cereblon）缺失和c-Myc上调与多发性骨髓瘤患者对来那度胺耐药相关。
Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15.
2
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in and models of multiple myeloma by blockade of Ikaros and MYC signaling.BET 溴结构域抑制剂 CPI203 通过阻断 Ikaros 和 MYC 信号通路提高来那度胺和地塞米松在多发性骨髓瘤 和 模型中的活性。
Haematologica. 2017 Oct;102(10):1776-1784. doi: 10.3324/haematol.2017.164632. Epub 2017 Jul 27.
3
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.大脑神经酰胺结合蛋白阿贡纳乌特2的表达对多发性骨髓瘤细胞的生长和存活起着重要作用。
BMC Cancer. 2016 May 3;16:297. doi: 10.1186/s12885-016-2331-0.
4
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.β-连环蛋白编码基因内的多态性影响多发性骨髓瘤的发展和治疗。
Leuk Res. 2015 Dec;39(12):1462-6. doi: 10.1016/j.leukres.2015.10.007. Epub 2015 Oct 19.
5
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.CRL4(CRBN)底物Ikaros和Aiolos的降解速率通过调控c-Myc和IRF4决定了来那度胺和泊马度胺在多发性骨髓瘤细胞中的不同活性。
Blood Cancer J. 2015 Oct 2;5(10):e354. doi: 10.1038/bcj.2015.66.
6
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.来氟米特通过靶向 PIM 调节骨髓瘤细胞中的 c-Myc 表达。
Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227.
7
Zeroing in on cereblon.聚焦于 Cereblon 蛋白。
Eur J Haematol. 2015 Jul;95(1):1-2. doi: 10.1111/ejh.12525. Epub 2015 Mar 16.
8
Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance.来那度胺维持治疗下多发性骨髓瘤患者外周调节性T细胞的流式细胞术分析
Int J Hematol. 2021 May;113(5):772-774. doi: 10.1007/s12185-021-03093-y. Epub 2021 Feb 8.
9
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.针对溴结构域和额外末端基序家族蛋白的蛋白靶向嵌合分子对多发性骨髓瘤的临床前模型具有活性。
Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.
10
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.来那度胺、多柔比星和地塞米松诱导治疗对初诊多发性骨髓瘤骨重塑和血管生成的影响。
Int J Cancer. 2019 Jul 15;145(2):559-568. doi: 10.1002/ijc.32125. Epub 2019 Jan 22.
引用本文的文献
1
Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics.血清 Cereblon（CRBN）水平可预测多发性骨髓瘤（MM）患者接受来那度胺 - 地塞米松治疗后的长期生存率，并与疾病特征相关。
Int J Mol Sci. 2025 Jun 30;26(13):6341. doi: 10.3390/ijms26136341.
2
Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities.多发性骨髓瘤中的翻译后修饰：耐药机制与治疗机遇
Biomolecules. 2025 May 12;15(5):702. doi: 10.3390/biom15050702.
3
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs.双重靶向CARM1和IKZF3：一种实现多发性骨髓瘤治疗中CARM1抑制与免疫调节药物协同作用的新方法。
Mol Ther Oncol. 2025 Feb 20;33(1):200952. doi: 10.1016/j.omton.2025.200952. eCollection 2025 Mar 20.
4
Exploration of degrons and their ability to mediate targeted protein degradation.降解结构域及其介导靶向蛋白质降解能力的探索。
RSC Med Chem. 2025 Jan 1. doi: 10.1039/d4md00787e.
5
Sustained yet non-curative response to lenalidomide in relapsed angioimmunoblastic T-cell lymphoma with acquired chidamide resistance: a case report with 10-year follow-up, genetic insights and literature review.来那度胺对复发的伴有获得性西达本胺耐药的血管免疫母细胞性T细胞淋巴瘤的持续但非治愈性反应：一例随访10年的病例报告、遗传学见解及文献综述
Front Oncol. 2024 Nov 27;14:1471090. doi: 10.3389/fonc.2024.1471090. eCollection 2024.
6
The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma.ADAR1调节的细胞质双链RNA感应途径是多发性骨髓瘤中来那度胺耐药的一种新机制。
Blood. 2025 Mar 13;145(11):1164-1181. doi: 10.1182/blood.2024024429.
7
Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.多发性骨髓瘤对免疫调节药物的耐药性：脑啡肽酶途径及其他
Haematologica. 2025 May 1;110(5):1074-1091. doi: 10.3324/haematol.2024.285636. Epub 2024 Nov 21.
8
Beneficial Effect of Olive Oil and Its Derivates: Focus on Hematological Neoplasm.橄榄油及其衍生物的有益作用：聚焦血液肿瘤
Life (Basel). 2024 Apr 30;14(5):583. doi: 10.3390/life14050583.
9
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.肿瘤和免疫细胞的药效学变化推动了伊布地骨在复发性和难治性多发性骨髓瘤中的临床作用机制。
Cell Rep Med. 2024 Jun 18;5(6):101571. doi: 10.1016/j.xcrm.2024.101571. Epub 2024 May 21.
10
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.靶向BRD9和IKZF3的协同作用作为多发性骨髓瘤的一种治疗策略
Cancers (Basel). 2024 Mar 28;16(7):1319. doi: 10.3390/cancers16071319.
本文引用的文献
1
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.双重抑制 DNMTs 和 EZH2 可以在不依赖 cereblon 的情况下克服骨髓瘤细胞对 IMiDs 的内在和获得性耐药。
Mol Oncol. 2018 Feb;12(2):180-195. doi: 10.1002/1878-0261.12157. Epub 2017 Dec 30.
2
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.来那度胺难治性多发性骨髓瘤患者中应用来那度胺联合低剂量环磷酰胺和泼尼松的 1/2 期研究。
Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.
3
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.难治性骨髓瘤的靶向测序显示CRBN和Ras信号通路基因的突变发生率很高。
Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.
4
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.免疫调节药物破坏 cereblon-CD147-MCT1 轴发挥抗肿瘤活性和致畸性。
Nat Med. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13.
5
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.一种用于检测多发性骨髓瘤患者样本中脑啡肽的双色免疫组织化学检测方法。
Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):695-702. doi: 10.1097/PAI.0000000000000246.
6
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.来那度胺导致多发性骨髓瘤细胞中 IKZF1 和 IKZF3 的选择性降解。
Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.
7
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.骨髓瘤药物来那度胺促进 cereblon 依赖性伊卡鲁素蛋白的降解。
Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.
8
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.测量 cereblon 作为来那度胺和泊马度胺反应或耐药的生物标志物，需要使用标准化试剂并了解基因复杂性。
Br J Haematol. 2014 Jan;164(2):233-44. doi: 10.1111/bjh.12622. Epub 2013 Oct 28.
9
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.高脑红蛋白表达与接受沙利度胺维持治疗的新诊断多发性骨髓瘤患者的生存改善相关。
Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101. Epub 2012 Dec 11.
10
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. cereblon 是来那度胺和泊马度胺免疫调节和抗增殖活性的直接蛋白靶标。
Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3.
Zotero 插件